ALX Oncology and Quantum Leap Report the First Patient Dosing of Evorpacept in the P-I Trial (I-SPY-P1-TRIAL) for Breast Cancer
- The first patient has been dosed in the P-I trial (I-SPY-P1-TRIAL) evaluating evorpacept (a CD47 blocker) + Enhertu in patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. The trial was sponsored by Quantum Leap Healthcare and manages all study operations
- The trial's objectives were to quickly assess the safety and determine the optimal dose of promising drug combinations that may be especially effective in treating early-stage, high-risk breast cancer
- The trial now includes serial testing of agents and combinations with the option to initiate non-chemotherapy combinations and escalate or de-escalate therapy based on patient response
Ref: Globenewswire | Image: ALX Oncology
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.